Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 1, 2013, Pages 664-667

  Allen, Charlotte A ^a   Babakhani, Farah ^b   Sears, Pam ^b   Nguyen, Ly ^b   Sorg, Joseph A ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b Optimer Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; FIDAXOMICIN; OP 1118; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; CELL GROWTH; CLOSTRIDIUM DIFFICILE; GROWTH INHIBITION; NONHUMAN; PRIORITY JOURNAL; SPORE GERMINATION;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CULTURE MEDIA; MICROBIAL SENSITIVITY TESTS; SPORES, BACTERIAL; TAUROCHOLIC ACID; VANCOMYCIN;

EID: 84872023885     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01611-12     Document Type: Article

References (23)

1. Rupnik M, Wilcox MH, Gerding DN. 2009. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 7:526-536.
2. Raibaud P, Ducluzeau R, Dubos F, Hudault S, Bewa H, Muller MC. 1980. Implantation of bacteria from the digestive tract of man and various animals into gnotobiotic mice. Am. J. Clin. Nutr. 33:2440-2447.
3. Wilson KH, Perini F. 1988. Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect. Immun. 56:2610-2614.
4. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. 2010. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467:711-713.
5. Lawley TD, Croucher NJ, Yu L, Clare S, Sebaihia M, Goulding D, Pickard DJ, Parkhill J, Choudhary J, Dougan G. 2009. Proteomic and genomic characterization of highly infectious Clostridium difficile 630 spores. J. Bacteriol. 191:5377-5386.
6. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, Gerding DN, Rood JI. 2009. Toxin B is essential for virulence of Clostridium difficile. Nature 458:1176-1179. doi:10.1038/nature07822.
7. Sorg JA, Sonenshein AL. 2008. Bile salts and glycine as cogerminants for Clostridium difficile spores. J. Bacteriol. 190:2505-2512.
8. Wilson KH, Kennedy MJ, Fekety FR. 1982. Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium difficile. J. Clin. Microbiol. 15:443-446.
9. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364:422-431.
10. Venugopal AA, Johnson S. 2012. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin. Infect. Dis. 54:568-574.
11. Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Sonenshein AL. 2012. Fidaxomicin inhibits spore production in Clostridium difficile. Clin. Infect. Dis. 55(Suppl 2):S162-S169.
12. Finegold SM, Molitoris D, Vaisanen ML, Song Y, Liu C, Bolanos M. 2004. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob. Agents Chemother. 48:4898-4902.
13. Tannock GW, Munro K, Taylor C, Lawley B, Young W, Byrne B, Emery J, Louie T. 2010. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 156:3354-3359.
14. Popoff MR, Rubin EJ, Gill DM, Boquet P. 1988. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect. Immun. 56:2299-2306.
15. Killgore G, Thompson A, Johnson S, Brazier J, Kuijper E, Pepin J, Frost EH, Savelkoul P, Nicholson B, van den Berg RJ, Kato H, Sambol SP, Zukowski W, Woods C, Limbago B, Gerding DN, McDonald LC. 2008. Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing. J. Clin. Microbiol. 46:431-437.
16. Sorg JA, Sonenshein AL. 2010. Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J. Bacteriol. 192:4983-4990.
17. Howerton A, Ramirez N, Abel-Santos E. 2011. Mapping interactions between germinants and C. difficile spores. J. Bacteriol. 193:274-282.
18. Liggins M, Ramirez N, Magnuson N, Abel-Santos E. 2011. Progesterone analogs influence germination of Clostridium sordellii and Clostridium difficile spores in vitro. J. Bacteriol. 193:2776-2783.
19. Ramirez N, Liggins M, Abel-Santos E. 2010. Kinetic evidence for the presence of putative germination receptors in Clostridium difficile spores. J. Bacteriol. 192:4215-4222.
20. Ramirez N, Abel-Santos E. 2010. Requirements for germination of Clostridium sordellii spores in vitro. J. Bacteriol. 192:418-425.
21. Akoachere M, Squires RC, Nour AM, Angelov L, Brojatsch J, AbelSantos E. 2007. Indentification of an in vivo inhibitor of Bacillus anthracis spore germination. J. Biol. Chem. 282:12112-12118.
22. Gut IM, Blanke SR, van der Donk WA. 2011. Mechanism of inhibition of Bacillus anthracis spore outgrowth by the lantibiotic nisin. ACS Chem. Biol. 6:744-752.
23. Artsimovitch I, Seddon J, Sears P. 2012. Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis. Clin. Infect. Dis. 55(Suppl 2):S127-S131.